{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:42:55Z","timestamp":1791276175371,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2006,3]]},"DOI":"10.1016\/j.neuropharm.2005.09.011","type":"journal-article","created":{"date-parts":[[2005,11,10]],"date-time":"2005-11-10T07:17:36Z","timestamp":1131607056000},"page":"345-353","source":"Crossref","is-referenced-by-count":16,"title":["Mefloquine selectively increases asynchronous acetylcholine release from motor nerve terminals"],"prefix":"10.1016","volume":"50","author":[{"given":"Joseph J.","family":"McArdle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence C.","family":"Sellin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Coakley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph G.","family":"Potian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kormakur","family":"Hognason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2005.09.011_bib1","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1113\/jphysiol.1975.sp010974","article-title":"On the role of mitochondria in transmitter release from motor nerve terminals","volume":"248","author":"Alnaes","year":"1975","journal-title":"J. Physiol."},{"key":"10.1016\/j.neuropharm.2005.09.011_bib2","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/j.2042-7158.1997.tb06047.x","article-title":"Stereoselective passage of mefloquine through the blood-brain barrier in the rat","volume":"49","author":"Baudry","year":"1997","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.neuropharm.2005.09.011_bib3","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1469-7793.2001.0217g.x","article-title":"Presynaptic function is altered in snake K+-depolarized motor nerve terminals containing compromised mitochondria","volume":"532","author":"Calupca","year":"2001","journal-title":"J. Physiol."},{"key":"10.1016\/j.neuropharm.2005.09.011_bib4","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1021\/jm980620z","article-title":"Synthesis, in vitro pharmacology, and molecular modeling of very potent tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease","volume":"42","author":"Camps","year":"1999","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2005.09.011_bib5","first-page":"203","article-title":"Clinical testing of new antimalarial compounds","volume":"50","author":"Canfield","year":"1974","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.neuropharm.2005.09.011_bib6","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.0402044101","article-title":"Potent block of Cx36 and Cx50 gap junction channels by mefloquine","volume":"101","author":"Cruikshank","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neuropharm.2005.09.011_bib7","doi-asserted-by":"crossref","first-page":"7495","DOI":"10.1523\/JNEUROSCI.19-17-07495.1999","article-title":"Mitochondrial clearance of cytosolic Ca(2+) in stimulated lizard motor nerve terminals proceeds without progressive elevation of mitochondrial matrix [Ca(2+)]","volume":"19","author":"David","year":"1999","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2005.09.011_bib8","doi-asserted-by":"crossref","first-page":"7290","DOI":"10.1523\/JNEUROSCI.20-19-07290.2000","article-title":"Stimulation-evoked increases in cytosolic [Ca(2+)] in mouse motor nerve terminals are limited by mitochondrial uptake and are temperature-dependent","volume":"20","author":"David","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2005.09.011_bib9","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1113\/jphysiol.2002.035196","article-title":"Mitochondrial Ca2+uptake prevents desynchronization of quantal release and minimizes depletion during repetitive stimulation of mouse motor nerve terminals","volume":"548","author":"David","year":"2003","journal-title":"J. Physiol."},{"issue":"Pt 1","key":"10.1016\/j.neuropharm.2005.09.011_bib10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1469-7793.1998.059bo.x","article-title":"Evidence that mitochondria buffer physiological Ca2+ loads in lizard motor nerve terminals","volume":"509","author":"David","year":"1998","journal-title":"J. Physiol."},{"key":"10.1016\/j.neuropharm.2005.09.011_bib11","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1475-2875-2-14","article-title":"The acute neurotoxicity of mefloquine may be mediated through a disruption of calcium homeostasis and ER function in vitro","volume":"2","author":"Dow","year":"2003","journal-title":"Malaria J."},{"key":"10.1016\/j.neuropharm.2005.09.011_bib12","first-page":"219","article-title":"Paranoid psychosis related to mefloquine antimalarial prophylaxis","volume":"45","author":"Fuller","year":"2002","journal-title":"P.N.G. Med. J."},{"key":"10.1016\/j.neuropharm.2005.09.011_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/science.158.3809.1702","article-title":"Action potentials without contraction in frog skeletal muscle fibers with disrupted transverse tubules","volume":"158","author":"Gage","year":"1967","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2005.09.011_bib14","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/0092-8674(94)90556-8","article-title":"Synaptotagmin I: a major Ca2+ sensor for transmitter release at a central synapse","volume":"79","author":"Geppert","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2005.09.011_bib15","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.bjp.0703638","article-title":"The antimalarial agent mefloquine inhibits ATP-sensitive K-channels","volume":"131","author":"Gribble","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2005.09.011_bib16","unstructured":"Hognason, K., Coakley, K., Rosenfeld, C., Sultatos, L.G., Sellin, L.C., McArdle, J.J., 2004. Mefloquine enhances spontaneous transmitter release and inhibits cholinesterase at the neuromuscular junction. Society for Neuroscience Abstracts 852.811."},{"key":"10.1016\/j.neuropharm.2005.09.011_bib17","first-page":"441","article-title":"Mefloquine concentration profiles during prophylactic dose regimens","volume":"112","author":"Kollaritsch","year":"2000","journal-title":"Wien. Klin. Wochenschr."},{"key":"10.1016\/j.neuropharm.2005.09.011_bib18","first-page":"221","article-title":"Effects of mefloquine on Ca2+ uptake and release by dog brain microsomes","volume":"331","author":"Lee","year":"1996","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"10.1016\/j.neuropharm.2005.09.011_bib19","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1440-1681.1985.tb00904.x","article-title":"The anticholinesterase activity of mefloquine","volume":"12","author":"Lim","year":"1985","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.neuropharm.2005.09.011_bib20","first-page":"663","article-title":"In vitro response of chloroquine-resistant Plasmodium falciparum to mefloquine","volume":"57","author":"Lopez Antunano","year":"1979","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.neuropharm.2005.09.011_bib21","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1128\/AAC.46.6.1680-1687.2002","article-title":"Mefloquine and new related compounds target the F(0) complex of the F(0)F(1) H(+)-ATPase of Streptococcus pneumoniae","volume":"46","author":"Martin-Galiano","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.neuropharm.2005.09.011_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1085\/jgp.61.1.1","article-title":"A study of the reinnervation of fast and slow mammalian muscles","volume":"61","author":"McArdle","year":"1973","journal-title":"J. Gen. Physiol."},{"key":"10.1016\/j.neuropharm.2005.09.011_bib23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0165-0270(81)90044-3","article-title":"Advantages of the triangularis sterni muscle of the mouse for investigations of synaptic phenomena","volume":"4","author":"McArdle","year":"1981","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.neuropharm.2005.09.011_bib24","unstructured":"McArdle, J.J., Sellin, L.C., 2003. Mefloquine (Lariam) increases spontaneous transmitter release from mature and immature motor nerve terminals. FASEB J. 17, A634 (abstract)."},{"key":"10.1016\/j.neuropharm.2005.09.011_bib25","unstructured":"McArdle, J.J., Sellin, L.C., Coakley, K.M., Potian, J.G., Quinones-Lopez, M.C., Rosenfeld, C.A., Sultatos, L.G., Hognason, K., 2005. Mefloquine inhibits cholinesterases and alters cholinergic synaptic transmission. Neuropharmacology, in press."},{"issue":"Pt 1","key":"10.1016\/j.neuropharm.2005.09.011_bib26","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1469-7793.1998.002bo.x","article-title":"The revival of the role of the mitochondrion in regulation of transmitter release","volume":"509","author":"Melamed-Book","year":"1998","journal-title":"J. Physiol."},{"key":"10.1016\/j.neuropharm.2005.09.011_bib27","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1021\/jm00292a008","article-title":"Antimalarials. 7. Bis(trifluoromethyl)-\u03b2(2-piperidyl)-4-quinolinemethanols","volume":"14","author":"Ohnmacht","year":"1971","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2005.09.011_bib28","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/00034983.1977.11687207","article-title":"The chemotherapy of rodent malaria, XXVIII. The development of resistance to mefloquine (WR 142,490)","volume":"71","author":"Peters","year":"1977","journal-title":"Ann. Trop. Med. Parasitol."},{"key":"10.1016\/j.neuropharm.2005.09.011_bib29","doi-asserted-by":"crossref","first-page":"370","DOI":"10.2165\/00002018-199512060-00003","article-title":"CNS adverse events associated with antimalarial agents. Fact or fiction?","volume":"12","author":"Phillips-Howard","year":"1995","journal-title":"Drug Safety"},{"key":"10.1016\/j.neuropharm.2005.09.011_bib30","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/0035-9203(95)90043-8","article-title":"Mefloquine-induced grand mal seizure during malaria chemoprophylaxis in a non-epileptic subject","volume":"89","author":"Pous","year":"1995","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.neuropharm.2005.09.011_bib31","doi-asserted-by":"crossref","first-page":"453","DOI":"10.5694\/j.1326-5377.1994.tb127536.x","article-title":"Seizure associated with mefloquine for malaria prophylaxis","volume":"161","author":"Ruff","year":"1994","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.neuropharm.2005.09.011_bib32","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.neuron.2004.12.056","article-title":"An isolated pool of vesicles recycles at rest and drives spontaneous neurotransmission","volume":"45","author":"Sara","year":"2005","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2005.09.011_bib33","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1128\/AAC.13.6.1011","article-title":"Antimalarial activities of various 4-quinolonemethanols with special attention to WR-142,490 (mefloquine)","volume":"13","author":"Schmidt","year":"1978","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.neuropharm.2005.09.011_bib34","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0009-9236(99)70010-X","article-title":"Population pharmacokinetics of mefloquine in patients with acute falciparum malaria","volume":"66","author":"Simpson","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2005.09.011_bib35","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1152\/jn.00456.2001","article-title":"Ca(2+)-dependent Ca(2+) clearance via mitochondrial uptake and plasmalemmal extrusion in frog motor nerve terminals","volume":"87","author":"Suzuki","year":"2002","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.neuropharm.2005.09.011_bib36","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1152\/jn.00012.2003","article-title":"Inhibition of mitochondrial Ca2+ uptake affects phasic release from motor terminals differently depending on external [Ca2+]","volume":"90","author":"Talbot","year":"2003","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.neuropharm.2005.09.011_bib37","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1476-5381.1990.tb15834.x","article-title":"Tetrahydroaminoacridine (tacrine) stimulates neurosecretion at mammalian motor endplates","volume":"100","author":"Thesleff","year":"1990","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2005.09.011_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s002280050240","article-title":"Neuro-psychiatric effects of antimalarials","volume":"52","author":"van Riemsdijk","year":"1997","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2005.09.011_bib39","doi-asserted-by":"crossref","first-page":"86","DOI":"10.4269\/ajtmh.1991.45.86","article-title":"Neuropsychiatric side effects after the use of mefloquine","volume":"45","author":"Weinke","year":"1991","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.neuropharm.2005.09.011_bib40","first-page":"1269","article-title":"Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials","volume":"167","author":"Wooltorton","year":"2002","journal-title":"C.M.A.J."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390805003540?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390805003540?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T15:42:00Z","timestamp":1554392520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390805003540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["S0028390805003540"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2005.09.011","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2006,3]]}}}